IAP12 Rec'd PCT/PTO 16 APR 2007

- Series	Lader the Pagerwork	Reduction Act of 1995, no person	ons are required to res	U.S. Patent and Trade	emark (PTO/SB/21 (09-06) for use through 03/31/2007. OMB 0651-0031 Office; U.S. DEPARTMENT OF COMMERCE unless it displays a valid OMB control number.		
in about the British		× × × × × × × × × × × × × × × × × × ×	one are required to res	Application Number	mation	10/509,036		
19 AP	R 2007 T I	RANSMITTA	AL '	Filing Date	-	September 27, 2004		
	-terriging \$200	FORM		First Named Inventor	r	Stuart M. PITSON		
Legal S Internationa	nan		·	Art Unit	-	Not Yet Assigned		
-		ed for all correspondence after	initial filing)	Examiner Name		Not Yet Assigned		
	Total Number	of Pages in This Submiss	on 26	Attorney Docket Nun	nber	229752003700		
		EN	CLOSURES	(Check all that ap	oply)			
-2	X Fee Transr	nittal Form	Drawing(s)			After Allowance Communication to TC		
	Fee /	Attached	Licensing-rel	ated Papers		Appeal Communication to Board of Appeals and Interferences		
	Amendmer	nt/Reply	x Petition			Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)		
	After	Final	Petition to Convert to a Provisional Application Power of Attorney, Revocation Change of Correspondence Address Terminal Disclaimer			Proprietary Information		
	Affida	avits/declaration(s)				Status Letter		
	Extension	of Time Request				X Other Enclosure(s) (please Identify below):		
	Express At	pandonment Request	Request for	Refund		Return Receipt Post Card Copy of Notification of Missing		
	Information	Disclosure Statement	CD, Number of CD(s) Landscape Table on CD			Requirements dated 3/8/05 xecuted Declaration		
	Certified Concument(opy of Priority s)						
		issing Parts/ Application	Remarks					
		y to Missing Parts under FR 1.52 or 1.53	Paper Copy o Computer-Re	rsuant to 37 CFR f Sequence Listing adable Disk of Se- Form cover sheet ignment	g	`,		
		SIGNATU	JRE OF APPLICA	ANT, ATTORNEY, (OR A	GENT		
	Firm Name	MORRISON & FOE	RSTER LLP					
	Signature	1						
	Printed name	Adam Keser			,			
	Date	April 16, 2007		Reg. No	0.	54 217		

PTO/SB/17 (02-07)
Approved for use through 02/28/2007. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE to a collection of information unless it displays a valid OMB control number.

Origer tite i up	elwork Reduction Act of	1000, no person are rec	quired to	respond to a conection		lete if Know		COLIN OF HUITIDE		
Fees pursuant to the										
1	TRANS			Filing Date		September 27, 2004				
, , , , ,			First Named Inventor Stuart M. PITSON							
	For FY 20)07	Examiner Name		ot Yet Assign	ed				
Applicant	claims small entity stat	us. See 37 CFR 1.27		Art Unit	N	ot Yet Assign	ed			
TOTAL AMOUN	T OF PAYMENT	(\$) 1,500.00)	Attorney Docket	No. 2	29752003700)	-		
METHOD OF	PAYMENT (check	all that apply)								
Check Credit Card Money Order None Other (please identify):										
X Deposit Acc	Count Deposit Account	Number: 03-1952 De	eposit Acc	count Name:	Morr	ison & Foerst	ter LLP			
For the a	above-identified depo	sit account, the Di	rector is	hereby authorize	ed to: (check	all that apply)				
x Ch	arge fee(s) indicated	below		Charg	e fee(s) indi	cated below, ex	cept for th	e filing fee		
	arge any additional t		nents o	f x Credit	any overpa	yments				
FEE CALCUL	· · · · · · · · · · · · · · · · · · ·	. 10 aliu 1.17	-					•		
	G, SEARCH, AND E	XAMINATION FEE	S	· · · · · · · · · · · · · · · · · · ·			•			
	•	LING FEES		ARCH FEES	EXAMIN	ATION FEES				
Application Ty	pe Fee (\$	Small Entity	Fee (\$	Small Entity	Fee (\$)	Small Entity Fee (\$)	Enne B	Paid (\$)		
Utility	300) <u>Fee (\$)</u> 150	500) <u>Fee (\$)</u> 250	200	100	<u> </u>	aiu (φ)		
Design	200	100	100	50	130	65				
Plant	200	100	300	150	160	80				
Reissue	300	150	500	250	600	300				
Provisional	200	100	0	0	0	0				
2. EXCESS CLA	IM FEES							Small Entity		
Fee Description							Fee (\$)	Fee (\$)		
	20 (including Reiss						50	25		
· ·	nt claim over 3 (incl	uding Reissues)					200	100		
Multiple depend							360	180		
Total Claims	Extra Claims	Fee (\$)	Fee	Paid (\$)		Multiple Dependent Claims Fee (\$) Fee Paid (\$)				
HP = highest numb	· 20 = per of total claims paid for				Fee	<u>: (3)</u>	Fee Paid (\$	7		
Indep. Claims	Extra Claims	Fee (\$)	Fee	Paid (\$)				_		
		× =		\\\						
	per of independent claims	paid for, if greater than	3.							
3. APPLICATIO			_							
If the specifica	tion and drawings e	ceed 100 sheets of	f paper	(excluding elections)	ronically file	ed sequence or	computer	n		
	er 37 CFR 1.52(e)), action thereof. See 3					my) for each a	uulliollai 30	J		
Total Sheets				additional 50 or fra		Fee (\$)	Fee !	Paid (\$)		
	- 100 =			(round up to a wh			=			
4. OTHER FEE(S)					_	Fees	Paid (\$)		
Non-English	Specification, \$13	0 fee (no small ent	ity disc	ount)				00.00		
Other (e.g., l	ate filing surcharge)	. 1453 Petition to	reviv	e unintentionally	y abandone	ea	1,5	00.00		
SUBMITTED BY										
Signature	au-c	·		Registration No.	54,217	Telephone	(703) 76	0-7301		
Name (Print/Type)	Adam Keser			(Attorney/Agent)	- ,	Date	April 16			
(i ilito i ype)	Additi Nesel					1 50.0	April 10	, 2001		

04/18/2007 MKAYPAGH 00000101 031952 10509036

130.00 DA 01 FC:1617

PTO/SB/64 (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

		PETITION ABANDO	Docket Number (Optional) 229752003700					
	First na	med invento	r: Stuart M. PITSON					
	Applica	tion No:	10/509,036		Art Unit:	Not Yet	Assigned	
	Filed:	Septembe	er 27, 2004		Examiner:	Not Y	et Assigned	
	Title:	METHOD	OF MODULATING CE	LLULAR ACTIVIT	Υ			
	P.O. Bo Alexano	ssioner for P ox 1450 dria, VA 223		eeded in completing	this form,	olease cor	ntact Petitions	
	T I		nation at (571) 272-3282.	de and for follows to			and the same of the same	
	The above-identified application became abandoned for failure to file a timely and proper reply to a notice or action by the United States Patent and Trademark Office. The date of abandonment is the day after the expiration date of the period set for reply in the office notice or action plus any extensions of time actually obtained.							
		P	APPLICANT HEREBY PE	TITIONS FOR REVI	VAL OF TH	IIS APPLI	CATION	
	N	OTE: A grar (1) (2) (3) (4)	ntable petition requires the Petition fee; Reply and/or issue fee Terminal disclaimer w filed before June 8, 19 Statement that the en	e; ith disclaimer fee – r 995; and for all desig	n application		and plant applications	
·	1. Peti	tion fee	y – fee \$	(37 CFR 1 17(m)) Applicar	nt claims s	mall entity status	
		See 37 CF		(37 01 10 10 10 10 10 10 10 10 10 10 10 10	у. Арріісаі	it Claims c	man criticy states.	
	Ľ	· .	small entity fee \$	1,500.00 (37 CF	FR 1.17(m))		
		oly and/or fee The reply	e and/or fee to the above-no	oted Office action in				
		the form o			Requireme	ents (ide	entify type of reply):	
		=						
	l R	L	nclosed herewith. fee and publication fee (if	applicable) of \$	•			
		has	been paid previously on					
]		nclosed herewith.	Page 1 of 2				
04/18/2007 MKAYPAG			10509036	, ugo , o. z				
02 FC:1453	500.00 I	Н						

PTO/SB/64 (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Terminal disclaimer with disclaimer fee								
Since this utility/plant application was filed on or after June 8, 1995, no terminal disclaimer is required.								
A terminal disclaimer (and disclaimer fee (37 CFR 1.20(d) or \$ for other than a small entity) di is enclosed herewith (see PTO/SB/63).) of \$ for a small entity sclaiming the required period of time							
4. STATEMENT: The entire delay in filing the required reply from the due date for the required reply until the filing of a grantable petition under 37 CFR 1.137(b) was unintentional. [NOTE. The United States Patent and Trademark Office may require additional information if there is a question as to whether either the abandonment or the delay in filing a petition under 37 CFR 1.137(b) was unintentional (MPEP 711.03(c), subsections (III)(C) and (D))].								
WARNING: Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.								
ale	Amril 46, 2007							
Signature	April 16, 2007 Date							
Oightitut C	Bale							
Adam Keser	54,217 Registration Number, if applicable							
Typed or printed name	Registration Number, if applicable							
MORRISON & FOERSTER LLP 1650 Tysons Blvd, Suite 400 McLean, Virginia 22102 Address	(703) 760-7301 Telephone Number							
1650 Tysons Blvd, Suite 400 McLean, Virginia 22102 Address								
1650 Tysons Blvd, Suite 400 McLean, Virginia 22102								
1650 Tysons Blvd, Suite 400 McLean, Virginia 22102 Address								
1650 Tysons Blvd, Suite 400 McLean, Virginia 22102 Address Enclosures: X Fee Payment								
1650 Tysons Blvd, Suite 400 McLean, Virginia 22102 Address Enclosures: X Fee Payment X Reply	Telephone Number							
1650 Tysons Blvd, Suite 400 McLean, Virginia 22102 Address Enclosures: X Fee Payment X Reply Terminal Disclaimer Form	Telephone Number							
1650 Tysons Blvd, Suite 400 McLean, Virginia 22102 Address Enclosures: X Fee Payment X Reply Terminal Disclaimer Form Additional sheets containing statements establish Other:	Telephone Number							
1650 Tysons Blvd, Suite 400 McLean, Virginia 22102 Address Enclosures: X Fee Payment X Reply Terminal Disclaimer Form Additional sheets containing statements establish	Telephone Number							
1650 Tysons Blvd, Suite 400 McLean, Virginia 22102 Address Enclosures: X Fee Payment X Reply Terminal Disclaimer Form Additional sheets containing statements establish Other:	Telephone Number							
1650 Tysons Blvd, Suite 400 McLean, Virginia 22102 Address Enclosures: X Fee Payment X Reply Terminal Disclaimer Form Additional sheets containing statements establish Other:	Telephone Number							
1650 Tysons Blvd, Suite 400 McLean, Virginia 22102 Address Enclosures: X Fee Payment X Reply Terminal Disclaimer Form Additional sheets containing statements establish Other:	Telephone Number							
1650 Tysons Blvd, Suite 400 McLean, Virginia 22102 Address Enclosures: X Fee Payment X Reply Terminal Disclaimer Form Additional sheets containing statements establish Other:	Telephone Number							

UNITED STATES DEPARTMENT OF COMMI United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Vingina 22313-1450 www.usplo.gov UNITED STATES DEPARTMENT OF COMMERCE

U.S. APPLICATION NUMBER NO.

FIRST NAMED APPLICANT

ATTY. DOCKET NO.

· **1**0/509,036

Stuart M Pitson

✓229752003700

INTERNATIONAL APPLICATION NO.

PCT/AU03/00388

I.A. FILING DATE

PRIORITY DATE

03/28/2003

03/28/2002

CONFIRMATION NO. 1337 371 FORMALITIES LETTER

OC000000015374062

25227 MORRISON & FOERSTER LLP 1650 TYSONS BOULEVARD SUITE 300 **MCLEAN, VA 22102**

Date Mailed: 03/08/2005

NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as a Designated / Elected Office (37 CFR 1.495).

- Copy of the International Application filed on 09/27/2004
- Copy of the International Search Report filed on 09/27/2004
- Copy of IPE Report filed on 09/27/2004
- Biochemical Sequence Listing filed on 09/27/2004
- Request for Immediate Examination filed on 09/27/2004
- U.S. Basic National Fees filed on 09/27/2004
- Priority Documents filed on 09/27/2004

The following items MUST be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

- Oath or declaration of the inventors, in compliance with 37 CFR 1.497(a) and (b), identifying the application by the International application number and international filing date.
- \$130 Surcharge for providing the oath or declaration later than 30 months from the priority date (37 CFR 1.492(e)) is required.

SUMMARY OF FEES DUE:

Total additional fees required for this application is \$130 for a Large Entity:

\$130 Late oath or declaration Surcharge.

The following items MUST be furnished within the period set forth below:

- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):
 - A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e) and PCT Rule 13ter.1(a)(ii).
 - APPLICANT MUST PROVIDE:
 - An initial or substitute computer readable form (CRF) of the "Sequence Listing."
 - A statement that the contents of the paper or compact disc and the computer readable form are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).
- For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:
 - For Rules Interpretation, call (703) 308-4216
 - To Purchase Patentin Software, call (703) 306-2600
 - For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

ALL OF THE ITEMS SET FORTH ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTHS FROM THE DATE OF THIS NOTICE OR BY 32 MONTHS FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

A copy of this notice MUST be returned with the response.

LAMONT M HUNTER

Telephone: (703) 308-9140 EXT 201

PART 1 - ATTORNEY/APPLICANT COPY

•	· · · · · · · · · · · · · · · · · · ·	
U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/509,036	PCT/AU03/00388	229752003700

FORM PCT/DO/EO/905 (371 Formalities Notice)

PATENT Docket No.22975-20037.00

DECLARATION FOR UTILITY PATENT APPLICATION

AS BELOW-NAMED INVENTORS, WE HEREBY DECLARE THAT:

Our residences, post office addresses, and citizenship are as stated below next to our names.

We believe we are the original, first and joint inventors of the subject matter which is claimed and for which a patent is sought on the invention entitled: A METHOD OF MODULATING CELLULAR ACTIVITY, the specification of which is attached hereto unless the following box is checked:

[X] was filed on 28 March 2003 as United States Application Serial No. and as PCT International Application No. PCT/AU03/00388

WE HEREBY STATE THAT WE HAVE REVIEWED AND UNDERSTAND THE CONTENTS OF THE ABOVE-IDENTIFIED SPECIFICATION, INCLUDING THE CLAIMS, AS AMENDED BY ANY AMENDMENT REFERRED TO ABOVE.

We acknowledge the duty to disclose information which is material to the patentability as defined in 37 C.F.R. § 1.56.

We hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT International application which designated at least one country other than the United States listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed:

Application No.	Country	Date of Filing (day/month/year)	Priority Claimed?
PS1448/02	Australia	28 March 2002	yes
PS1538/02	Australia	5 April 2002	yes
PS1621/02	Australia	8 April 2002	yes
2002951668	Australia	19 September 2002	yes
2003900230	Australia	21 January 2003	yes

We hereby claim benefit under 35 U.S.C. § 119(e) of any United States provisional application(s) listed below:

Application Serial No.	Filing Date
*	

We hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s), or § 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. § 112, we acknowledge the duty to disclose information which is material to patentability as defined in 37 C.F.R. § 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application.

Application Serial No.	Filing Date	Status	and the state of t	
PCT/AU03/00388	28 March 2003	□ Patented	□Pending	□Abandoned

We hereby appoint the following attorneys and agents to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

Lisa A. Amii (kcg No. 48,199) Mehran Arjomand (Kog No. 48,231) Sanjay S. Bagade (Reg No. 42,280) Shantanu Basu (Reg No. 43,518) Vincent J. Belusko (Reg No. 30,820) Kimberly A. Bolin (Reg No. 44,546) Tyler S. Brown (Reg No. 36,465) A. Randall Camacho (Reg No. 46,595) Robert K. Cerpa (Reg No. 39,933) Alex Chartove (Reg No. 31,942) Thomas E. Ciotti (Reg No. 21,013) Matthew M. D'Amore (Reg No. 42,457) Peter Davis (Reg No. 36,119) Karen B. Dow (Reg No. 29,684) Carolyn A. Favorito (Reg No. 39,183) Hector Gallegos (Reg No. 40,614) Deborah S. Gladstein (Reg No. 43,636) Kenneth R. Glick (Reg No. 28,612) Johney U. Han (Reg No. 45,565) Alan S. Hodes (Reg No. 38,185) Kelvan P. Howard (Reg No. P48,999) Jill A. Jacobson (Reg No. 40,030) Madeline I. Johnston (Reg No. 36,174) Ararat Kapouytian (Reg No. 40,044) Cameron A. King (Reg No. 41,897) Kawai Lau (Reg No. 44,461) Rimas T. Lukas (Reg No. 46,451) Gladys H. Monroy (Reg No. 32,430) Kate H. Murashige (Reg No. 29,959)

Randolph Ted Apple (Reg No. 36,429) Laurie A. Axford (Reg No. 35,053) Erwin J. Basinski (Reg No. 34,773) Richard R. Batt (Reg No. 43,485) Jonathan Bockman (Reg No. 45,640) Barry E. Bretschneider (Reg No. 28,055) Nicholas Buffinger (Reg No. 39,124) Mark R. Carter (Reg No. 39,131) Peng Chen (Reg No. 43,543) Thomas Chuang (Reg No. 44,616) Cara M. Coburn (Reg No. 46,631) Raj S. Davé (Reg No. 42,465) David Devernoe (Reg No. 50,128) Stephen C. Durant (Reg No. 31,506) David L. Fehrman (Reg No. 28,600) Thomas George (Reg No. 45,740) Debra J. Glaister (Reg No. 33,888) Bruce D. Grant (Reg No. 47,608) Douglas G. Hodder (Reg No. 41,840) Charles D. Holland (Reg No. 35,196) Peter Hsich (Reg No. 44,780) Wayne Jaeschke, Jr. (Reg No. 38,503) Parisa Jorjani (Reg No. 46,813) Richard C. Kim (Reg No. 40,046) Lawrence B. Kong (Reg No. P49,043) Glenn Kubota (Reg No. 44,197 Michael J. Mauriel (Reg No. 44,226) Philip A. Morin (Reg No. P-45,926) Mabel Ng (Reg No. P48,922)

Martin M. Noonen (Reg No. 44,264) Phillip Reilly (Reg No. 41,415) Debra A. Shetka (Reg No. 33,309) Kevin R. Spivak (Reg No. 43,148) Thomas L. Treffert (Reg No. P48,279) Michael R. Ward (Reg No. 38,651) Todd W. Wight (Reg No. 45,218) Frank Wu (Reg No. 41,386) Peter J. Yim (Reg No. 44,417) Karen R. Zachow (Reg No. 46,332)

Catherine M. Polizzi (Reg No. 40,130) Robert E. Scheid (Reg. No. 42,126) Terri Shieh-Newton (Reg No. 47,081) Stanley H. Thompson (Reg No. 45,160) Brenda J. Wallach (Reg No. 45,193) E. Thomas Wheelock (Reg No. 28,825) Eric Witt (Reg No. 44,408) David T. Yang (Reg No. 44,415) George C. Yu (Reg No. 44,418)

Please direct all communications to:

1650 Tysons Boulevard, Suite 300 McLean, Virginia 22102

Please direct all telephone calls to Barry E. Bretschneider at (703) 760-7743

We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under § 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Name:

Stuart M. PITSON

Residence:

1B Threlfall Avenue, Norwood, South Australia 5067, Australia

Citizenship:

Australia

Post Office Address: "same as above"

Name: Residence:

Pu XIA

97 Shakespeare Avenue, Magill, South Australia 5072, Australia

Citizenship:

Australia

Post Office Address: "same as above"

Name:

Residence:

3 Railway Terrace South, Goodwood, South Australia 5034,

Australia

Australia

Citizenship: Post Office Address: "same as above

13 Dec 2004 1:36PM

MEDVET IP OFFICE

08 9222 3411

P. 11

121-12-04

Julia Zebal.

NAMO: Residence:

Tulia R. VERWEY ZEBOL TO 21-12-04
29 Highfield Drive, Hillionia, South Australia 21:19: Amerika
Australia 12/15 Ruckky Rd., South Yorka, Victoria, 8141.

Citizenship: Australia
Post Office Address: "same as above"

BADY WALLE MONO

Name:

Mathew A. VADAS

Residence: Citizenship:

\$ Branch Road, Stirling, South Australia 5132, Australia

VMACATIV

Post Office Address:

Date

Name: Brian W. WATTENBERG Residence:

Brown Cancer Contro, 529 S. Jackson Street, Louisville,

Keetucky 40202, United States Citizerahip; Attatralia

Post Office Address:

Date Name:

Residence: Citizensbip:

Post Office Address:

Docket No.22975-20037.00 Application No.

× Date Name: Julia R. VERWEY Residence: 27 Highfield Drive, Hillbank, South Australia 5112, Australia Citizenship: Australia Post Office Address: "same as above" Name: Mathew A. VADAS Residence: 8 Branch Road, Stirling, South Australia 5152, Australia Citizenship: Post Office Address: Date Name: Brian W. WATTENBERG Residence: Brown Cancer Centre, 529 S. Jackson Street, Louisville, Kentucky 40202, United States Citizenship: Australia Post Office Address: Date Name: Residence: Citizenship:

Post Office Address:

Dec 2004 8:02AM

MEDVET IP OFF SE

09 8222 3411

p. 11

Date

Name: Residence: Julia R. ERWEY

27 High !ld Drive, Hillbank, South Australia 5112, Australia

Ciazenship: Australi: Post Office Address: "sums as bove"

Name: Residence:

Mathew

& Branci doad, Stirling, South Australia 5152, Australia

Austali:

Citizenship: Post Office Address:

Name:

Brisi WATTENBERG

Residence

Brown

anser Centre, 529 S. Jackson Street, Louisville,

Kentucky 40202, United Smit Citizenship: Australia

Post Office Address:

Date

Name:

Residence:

Citizonabig:

Post Office Address:

Dacket No.22975-20037,00 Application No.

Docket No.: 229752003700

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Stuart PITSON et al.

Application No.: 10/509,036

•

Filed: September 27, 2004 Art Unit: Not Yet Assigned

For: METHOD OF MODULATING CELLULAR

ACTIVITY

Examiner: Not Yet Assigned

Confirmation No.: 1337

STATEMENT PURSUANT TO 37 CFR 1.821(f)

Petition Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In response to the Notification of Missing Requirements mailed on March 8, 2005, the undersigned hereby states that the content of the attached paper copy of the sequence listing and the computer readable copy of the sequence listing submitted in accordance with 37 C.F.R. §§ 1.821-1.825, are identical. The submission includes no new matter.

Applicants request consideration and entry of the Sequence Listing paper copy and computer readable copy. Pursuant to 37 C.F.R. 1.77, please enter the paper copy of the Sequence Listing after the Abstract.

In the event the U.S. Patent and Trademark Office determines that an extension and/or other relief is required, applicants petition for any required relief including extensions of time and

Application No.: 10/509,036 Docket No.: 229752003700

authorizes the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing docket no. **229752003700**.

Dated: April 16, 2007

Respectfully submitted,

Adam Keser

Registration No.: 54,217 MORRISON & FOERSTER LLP 1650 Tysons Blvd, Suite 400 McLean, Virginia 22102

(703) 760-7301

1

SEQUENCE LISTING

10

<110>	Medvet Science Pty Ltd
<120>	A Method of Modulating Cellular Activity
<130>	12185280/TDO
<150>	2003900230
<151>	2003-01-21
<150>	2002951668
<151>	2002-09-19
<150>	PS1448
<151>	2002-03-28
<150>	PS1538
<151>	2002-04-05
<150>	PS1621
	2002-04-08
<160>	14
c170>	PatentIn version 3.1
71.02	
<210>	1
<211>	10 :
<212>	PRT
<213>	mammalian
<400>	1
Lys Th	ar Pro Ala Ser Pro Val Val Val Gln

PCT/AU03/00388

```
<210> 2
```

<211> 14

<212> PRT

<213> mammalian

<400> 2

Cys Gly Ser Lys Thr Pro Ala Ser Pro Val Val Val Gln Gln

1 5 10

<210> 3

<211> 11

<212> PRT

<213> mammalian

<400> 3

Ser Lys Thr Pro Ala Ser Pro Val Val Gln
1 5 10

<210> 4

<211> 21

<212> DNA

<213> mammalian

<400> 4

cggctgctgg cgcccatgaa c

21

<210> 5

<211> 24

<212> DNA

<213> mammalian

<400> 5

tgtggacctc gaggctgaga agta

24

aagacacctg cggcgcccgt tgtg

<210>	6	
<211>	27	
<212>	DNA	
<213>	mammalian	
•		
<400>	6	
agtgaga	aagg ctcggcgcct gggggag	27
<210>	7	
<211>	20	
<212>	DNA	
<213>	mammalian	
<400>	7	
aagagt	gggc gccaagacac	20
<210>	8	
<211>	28	
<212>	DNA	
<213>	mammalian	
	8	
aagagt	ggga tecaaggege etgeetee	28
<210>		
<211>	24	
<212>		
<213>	mammalian	
<400>	9	
aagaca	ceta eggegeeeat tata	24

PCT/AU03/00388

WO 03/082322

<210> 10

<211> 24

<212> DNA

<213> mammalian

<400> 10

acacctgccg aaccggttgt ggtc

24

<210> 11

<211> 19

<212> DNA

<213> mammalian

<400> 11

tctcactggg cagtggtgc

19

<210> 12

<211> 384

<212> PRT

<213> mammalian

<400> 12

Met Asp Pro Ala Gly Gly Pro Arg Gly Val Leu Pro Arg Pro Cys Arg

1 5 10 15

Val Leu Val Leu Leu Asn Pro Arg Gly Gly Lys Gly Lys Ala Leu Gln
20 25 30

Leu Phe Arg Ser His Val Gln Pro Leu Leu Ala Glu Ala Glu Ile Ser 35 40 45

Phe Thr Leu Met Leu Thr Glu Arg Arg Asn His Ala Arg Glu Leu Val 50 55 60

Arg Ser Glu Glu Leu Gly Arg Trp Asp Ala Leu Val Val Met Ser Gly

5/6

PCT/AU03/00388

Asp Gly Leu Met His Glu Val Val Asn Gly Leu Met Glu Arg Pro Asp - Trp Glu Thr Ala Ile Gln Lys Pro Leu Cys Ser Leu Pro Ala Gly Ser Gly Asn Ala Leu Ala Ala Ser Leu Asn His Tyr Ala Gly Tyr Glu Gln Val Thr Asn Glu Asp Leu Leu Thr Asn Cys Thr Leu Leu Cys Arg Arg Leu Leu Ser Pro Met Asn Leu Leu Ser Leu His Thr Ala Ser Gly Leu Arg Leu Phe Ser Val Leu Ser Leu Ala Trp Gly Phe Ile Ala Asp Val Asp Leu Glu Ser Glu Lys Tyr Arg Arg Leu Gly Glu Met Arg Phe Thr Leu Gly Thr Phe Leu Arg Leu Ala Ala Leu Arg Thr Tyr Arg Gly Arg Leu Ala Tyr Leu Pro Val Gly Arg Val Gly Ser Lys Thr Pro Ala Ser Pro Val Val Val Gln Gln Gly Pro Val Asp Ala His Leu Val Pro Leu Glu Glu Pro Val Pro Ser His Trp Thr Val Val Pro Asp Glu Asp Phe Val Leu Val Leu Ala Leu Leu His Ser His Leu Gly Ser Glu Met

29

Phe Al	a Ala 275		Met	Gly	Arg	Сув 280	Ala	Ala	Gly	Val	Met 285	His	Leu	Phe		
Tyr Va	_	Ala	Ġlý	'Val	Ser 295	Arg	Ala	Met	Leu	Leu 300	Arg	Leu	Phe	Leu	•• •	
Ala Me	et Glu	Lys	Gly	Arg 310	His	Met	Glu	Tyr	Glu 315	Сув	Pro	Tyr	Leu	Val 320		
Tyr Va	al Pro	Val	Val 325	Ala	Phe	Arg	Leu	Glu 330	Pro	ГУв	Asp	Gly	Lув 335	Gly		
Met Ph	ne Ala	Val 340	Asp	Gly	Glu	Leu	Met 345	Val	Ser	Glu	Ala	Val 350	Gln	Gly		
Gln Va	al His 355		Asn	Tyr	Phe	Trp 360	Met	Val	Ser	Gly	Сув 365	Val	Glu	Pro		
Pro Pr		Trp	Lys	Pro	Gln 375	Gln	Met	Pro	Pro	Pro 380	Glu	Glu	Pro	Leu		
<210>	13															
<211>	26															
<212>	DNA															
<213>	prim	ers									,					
<400>	13															
taaago	ettge	cacc	atgg	tg a	gcaa	9										26
<210>	14		•													
<211>	29															
<212>	DNA															
<213>	prim	ers														

atggatccat cttgtacagc tcgtccatg

RECORDATION FORM COVER SHEET PATENTS ONLY To the Director of the U.S. Patent and Trademark Office: Please record the attached documents or the new address(es) below. 2. Name and address of receiving party(ies) 1. Name of conveying party(ies): Stuart M. PITSON (11/30/2004), Pu XIA Medvet Science Pty Ltd. (11/30/2004), Paul A. MORETTI (11/30/2004), Julia R. ZEBOL (12/21/2004), Internal Address: Additional name(s) of conveying party(ies) attached? | x | Yes Street Address: 3. Nature of conveyance/Execution Date(s): 38 Payneham Road Stepney, South Australia 5069 Execution Date(s): in parentheses after inventor name Australia x Assignment Merger Change of Name Security Agreement Joint Research Agreement City: ___ Government Interest Assignment State: Executive Order 9424, Confirmatory License Country: _ Zip: Additional name(s) & address(es) Yes attached? 4. Application or patent number(s): This document is being filed together with a new application. A. Patent Application No.(s) B. Patent No.(s) 10/509.036 Additional numbers attached? 5. Name and address to whom correspondence 6. Total number of applications and concerning document should be mailed: patents involved: Name: Barry E. Bretschneider MORRISON & FOERSTER LLP 7. Total fee (37 CFR 1.21(h) & 3.41) \$ 40.00 Internal Address: Atty. Dkt.: 229752003700 Authorized to be charged by credit card Street Address: 1650 Tysons Blvd, Suite 300 Authorized to be charged to deposit account Х **Enclosed** None required (government interest not affecting title) City: McLean 8. Payment Information 22102 Last 4 Numbers a. Credit Card State: Zip: **Expiration Date** (703) 760-7743 Phone Number: (703) 760-7777 03-1952 b. Deposit Account Number Fax Number: BBretschneider@mofo.com Authorized User Name Barry E. Bretschneider Email Address: 9. Signature: April 16, 2007 Date Signature Adam Keser - 54,217 Total number of pages including cover 6 sheet, attachments, and documents: Name of Person Signing

Form PTO-1595 RECORDATION FORM COVER SHEET (continued)								
Additional Conveying P	arty(ies)/Execution D	ate(s) (1. Continued):						
Mathew A. VADAS (11/30/2	004), and Brian W. WATT	ENBERG (12/6/2004)						
Additional Assignees (2	2. Continued):	·						
Assignee Name:			-					
Internal Address: Street Address:								
City:	_ State:	Country:	Zip:					
Assignee Name:			-					
Internal Address: Street Address:								
City:	State:	Country:	Zip:					
Assignee Name:								
Internal Address: Street Address:								
City:	State:	Country:	_ Zip:					
Additional Applications	and/or Patents (4. Co	ontinued):						
Additional Patent Application Numl 4A. Continued:	Additional Patent Numbers 4B. Continued:							
		,						
	Additional numbers attached?	Yes No						

Docket No.: 229752003700

US PATENT Attorney Docket No. 22975-20037.00

ASSIGNMENT

WHEREAS, I/WE

Stuart M. PITSON, an Australian citizen of 1B Threlfall Avenue, Norwood, South Australia 5067, Australia;

Pu XIA, an Australian citizen of 97 Shakespeare Avenue, Magill, South Australia 5072, Australia; Paul A. MORETTI, an Australian citizen of 3 Railway Terrace South, Goodwood, South Australia; 5034, Australia;

Julia R. VERWEY, an Australian citizen of 27 Highfield Drive, Hillbank, South Australia 5112, Australia;

Mathew A. VADAS, an Australian citizen of 8 Branch Road, Stirling, South Australia 5152, Australia; Brian W. WATTENBERG, an Australian citizen of Brown Cancer Centre, 529 S. Jackson Street, Louisville, Kentucky 40202, United States

hereinafter referred to as Assignor (collectively if more than one inventor is listed above), have invented certain new and useful improvements in A method of modulating cellular activity

the specification of which:

(a)	[]	was executed on even date herewith;
(ъ)	[]	was filed on as [.] Application No.
		[] Express Mail No., as Application No. not yet known and was amended on
(c)	(x)	was described and claimed in PCT International Application
		and as amended under PCT Article 10 on
		under PCT Article 34 on (if any).
AND WHERE		Pruling of special Road, Stephey, South Australia 5069
Medvet Sc	ienc	/ A V) A/VII, U1 ZV/ 1//// 2V / XV - XV/ MOS - LINONOS - LINONOS - V AVIIII. A V - L - 1' - #AAA - 1
		AVS Malice

(hereinafter referred to as Assignee) desires to acquire the entire rights, title, and interest in and to the said improvements with respect to the United States of America, its territories and possessions.

NOW, THEREFOR, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Assignor hereby acknowledges that it has sold, assigned, transferred and set over, and by these presents does hereby sell, assign, transfer and set over, unto Assignee, its successors, legal representatives and assigns, the entire right, title, and interest in the United States of America, and its territories and possessions in, to and under said improvements, and any Patent Applications in the United States of America and all divisions, renewals and continuations thereof, and all Patents of the United States of America which may be granted thereon and all reissues and extensions thereof, and all rights of priority under International Conventions; and Assignor hereby authorizes and requests the Commissioner of Patents of the United States of America to issue all Patents for said improvements to Assignce, its successors, legal representatives and assigns, in accordance with the terms of this instrument.

AND ASSIGNOR HEREBY covenants and agrees that it will communicate to Assignee, its successors, legal representatives and assigns, any facts known to it respecting said improvements, and testify in any legal proceeding, sign all lawful papers, execute all divisional, continuing and reissue applications, make all rightful oaths and generally do everything possible to aid Assignee, its successors, legal representatives and assigns, to obtain and enforce proper patent protection for said improvements in the United States of America.

IN TESTIMONY WHEREOF, Assignor intending to be legally bound has hereunto affixed its signature.

This 30 th day of Nexterribe!", 2004

Witness

Signature of Stuart M. PITSON

Witness

US PATENT Attorney Docket No. 22975-20037.00

This 30 day of Newson, 2004 Witness	Signature of Paxia
This 30th day of NOVEMBER, 2004 Witness	Signature of Paul A. MORETTI
Thisday of, 2004	X
Witness	Signature of Julia R. VERWEY
This 30th day of NOVEMBER, 2004	Signature of Mathew A. VADAS

13 Dec 2004 1:35PM MEDVET IP OFFICE

08 8222 3411

PATENT Attorney Docket No. 22975-20037.00

This 30 day of Name 12, 2004

... This 30th day of NOVEMBER

SIGNATURE OF JULIA R. VARNEY
25 BOL 78 21.18.04

This 30th day of NOVEMBER, 2014

Signature of

I Dec 2004 7:55AM

G9 9222 3411

	US PATENT Anomey Docket No. 22975-20037.00
* This 6 day of December 2004 * Witness Possberry	Signature of Brian W. WATTENBERG
Thisday of, 2004 Witness	Signature of
Thisday of, 2004 Winters	Signature of
This	Signeture of

MEDVET IP OFF SE

Wimess